Elbasvir and grazoprevir for the treatment of hepatitis C

被引：3

作者：

Wang, Szu-Jen ^{[1
,2
]}

Huang, Chung-Feng ^{[3
,4
]}

Yu, Ming-Lung ^{[1
,3
,4
]}

机构：

[1] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan

[2] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan

[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung 807, Taiwan

[4] Kaohsiung Med Univ, Coll Med, Fac Internal Med, Kaohsiung, Taiwan

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2021年 / 19卷 / 09期

关键词：

Direct-acting antivirals; elbasvir; grazoprevir; hepatitis C virus; genotype; 1; or; 4; sustained viral response; efficacy; safety; tolerability; drug-drug interaction; VIRUS GENOTYPE 1; HCV NS5A INHIBITOR; INFECTION; ELBASVIR/GRAZOPREVIR; ASSOCIATION; EFFICACY; MK-8742; SAFETY; TRANSPLANTATION; COINFECTION;

D O I：

10.1080/14787210.2021.1874351

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Hepatitis C is one of the leading causes of chronic liver disease. The direct-acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a sustained virological response rate >95% in different populations. Area covered: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR). Expert opinion: EBR/GZR is a combination of NS5A and NS3/4A inhibitors. The performance in the EBR/GZR combination's safety and tolerability is appreciated in clinical treatment. EBR/GZR also has a higher barrier to resistance-associated substitutions. Based on clinical trials and real-world experience, elbasvir/grazoprevir is effective in the HCV GT1, 4 infections.

引用

页码：1071 / 1081

页数：11

共 50 条

[1] Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C
Carrion, Andres F.
Martin, Paul
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 883 - 890
[2] Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C
Sulejmani, Nimisha
Jafri, Syed-Mohammed
Gordon, Stuart C.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 353 - 361
[3] Grazoprevir + elbasvir for the treatment of hepatitis C virus infection
Alric, Laurent
Bonnet, Delphine
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (05) : 735 - 742
[4] Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1489): : 25 - 27
[5] Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
Chandana Papudesu
Shyamasundaran Kottilil
Shashwatee Bagchi
Hepatology International, 2017, 11 : 152 - 160
[6] Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection
Landaverde, Carmen
Wells, Jennifer
Hamner, Rebekah
Goldstein, Janie L.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (04) : 419 - 429
[7] Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
Papudesu, Chandana
Kottilil, Shyamasundaran
Bagchi, Shashwatee
HEPATOLOGY INTERNATIONAL, 2017, 11 (02) : 152 - 160
[8] Erratum to: Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
Chandana Papudesu
Shyamasundaran Kottilil
Shashwatee Bagchi
Hepatology International, 2017, 11 : 315 - 316
[9] Elbasvir/Grazoprevir (Zepatier) for Hepatitis C Virus Infection
Early, Jessica
Maxted, George
AMERICAN FAMILY PHYSICIAN, 2017, 95 (06) : 393 - 394
[10] Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
Morikawa, Kenichi
Nakamura, Akihisa
Shimazaki, Tomoe
Sakamoto, Naoya
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2749 - 2756

← 1 2 3 4 5 →